Brokerages Set Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Price Target at $5.50

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been assigned a consensus rating of “Hold” from the five research firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $5.50.

A number of equities analysts have weighed in on MRVI shares. Wall Street Zen raised shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Weiss Ratings raised shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. UBS Group restated a “reduce” rating on shares of Maravai LifeSciences in a report on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $6.00 target price on shares of Maravai LifeSciences in a research report on Friday, May 8th. Finally, Wells Fargo & Company boosted their price target on Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a research report on Friday, May 8th.

Insider Activity at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total value of $126,500.00. Following the transaction, the general counsel directly owned 360,767 shares of the company’s stock, valued at $1,825,481.02. The trade was a 6.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MRVI. Royal Bank of Canada grew its stake in Maravai LifeSciences by 49.0% during the first quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock worth $27,000 after buying an additional 3,209 shares during the period. Barclays PLC raised its stake in shares of Maravai LifeSciences by 3.0% in the 4th quarter. Barclays PLC now owns 172,281 shares of the company’s stock valued at $560,000 after acquiring an additional 5,057 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Maravai LifeSciences by 12.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 46,528 shares of the company’s stock valued at $112,000 after acquiring an additional 5,160 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Maravai LifeSciences by 2.7% during the 1st quarter. Bank of New York Mellon Corp now owns 343,643 shares of the company’s stock valued at $973,000 after acquiring an additional 8,955 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Maravai LifeSciences by 121.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 18,021 shares of the company’s stock valued at $43,000 after acquiring an additional 9,870 shares in the last quarter. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Stock Down 3.9%

Shares of NASDAQ:MRVI opened at $6.59 on Thursday. The company has a current ratio of 5.91, a quick ratio of 4.96 and a debt-to-equity ratio of 0.72. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -9.28 and a beta of 0.65. The stock’s 50-day moving average price is $5.71 and its two-hundred day moving average price is $4.26. Maravai LifeSciences has a 12-month low of $1.99 and a 12-month high of $7.44.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.06. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. The company had revenue of $65.84 million during the quarter, compared to the consensus estimate of $53.00 million. On average, research analysts forecast that Maravai LifeSciences will post -0.2 EPS for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.